These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 4411274)

  • 1. [Three-year follow-up results of the first clinical study on the daily and twice-weekly administrations of rifampicin, investigated by the Tuberculosis Research Committee, Ryoken (author's transl)].
    Kekkaku; 1974 Apr; 49(4):107-12. PubMed ID: 4411274
    [No Abstract]   [Full Text] [Related]  

  • 2. [A five year follow-up study of antituberculosis chemotherapy with and without rifampicin (author's transl)].
    Matsumiya T; Yoshida F; Inoue M; Yoshimura M; Ogawa T; Yoshida R; Ishii A
    Kekkaku; 1980 Feb; 55(2):43-51. PubMed ID: 7373965
    [No Abstract]   [Full Text] [Related]  

  • 3. [Investigation on failures in the treatment of pulmonary tuberculosis with rifampicin. Tuberculosis Research Committee. RYOKEN].
    Kekkaku; 1984 Feb; 59(2):91-104. PubMed ID: 6431172
    [No Abstract]   [Full Text] [Related]  

  • 4. [A follow-up study on cases treated with daily and intermittent regimens of rifampicin (author's transl)].
    Yamamoto K; Aizawa H; Ochi T; Kawamori Y; Kakuno J
    Kekkaku; 1974 Sep; 49(9):289-93. PubMed ID: 4444092
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical study on rifampicin applied every other day for severe cavitary pulmonary tuberculosis (author's transl)].
    Kitatani F; Fujimoto S; Asahi T; Konishiike J; Sera Y
    Kekkaku; 1974 May; 49(5):133-8. PubMed ID: 4408937
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic effects and side effects of rifampicin administered daily or twice-weekly.
    Gomi J; Aoyagi T
    Scand J Respir Dis Suppl; 1973; 84():145-52. PubMed ID: 4522070
    [No Abstract]   [Full Text] [Related]  

  • 7. [A long-term observation on previously treated cases of pulmonary tuberculosis retreated with rifampicin for more than six months (author's transl)].
    Tamura M; Takazawa N; Asada T; Ikegaki H; Yamada M; Kushiro S; Tada T
    Kekkaku; 1979 May; 54(5):285-95. PubMed ID: 113607
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative study of the treatment of pulmonary tuberculosis by a combination of rifampicin and isoniazid administered daily and twice weekly for a year].
    Decroix G; Kreis B; Sors C; Birenbaum J; Le Lirzin M; Canetti G
    Rev Tuberc Pneumol (Paris); 1971; 35(1):39-54. PubMed ID: 5559724
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparison of therapeutic effects of rifampicin 450 mg daily and 600 mg three times weekly on the previously treated pulmonary tuberculosis patients].
    Yamamoto M; Mizutani A; Nakamura H; Hirose H; Nagata A
    Kekkaku; 1973 May; 48(5):197-202. PubMed ID: 4732658
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical results of retreatment using rifampicin for more than 12 months for pulmonary tuberculosis (author's transl)].
    Urakami E; Nagasawa S
    Kekkaku; 1973 Sep; 48(9):411-6. PubMed ID: 4772413
    [No Abstract]   [Full Text] [Related]  

  • 11. [A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous].
    He GJ
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Feb; 16(2):73-6, 122. PubMed ID: 8251027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aggravation and relapse of tuberculosis before and after the clinical application of rifampicin (author's transl)].
    Shimizu T
    Kekkaku; 1976 Dec; 51(12):507-8. PubMed ID: 1018407
    [No Abstract]   [Full Text] [Related]  

  • 13. [The sensitivity of Mycobacterium tuberculosis to rifampicin and its clinical effectiveness (author's transl)].
    Chen HL
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Feb; 3(2):104-5. PubMed ID: 6774865
    [No Abstract]   [Full Text] [Related]  

  • 14. [Intermittent rifampicine treatment of experimental tuberculosis. Morpho-pathological study (author's transl)].
    Diaconitza G; Lutzesco L
    Acta Tuberc Pneumol Belg; 1974; 65(2):228-42. PubMed ID: 4213882
    [No Abstract]   [Full Text] [Related]  

  • 15. [A clinical trial of short-course chemotherapy for pulmonary tuberculosis patients (author's transl)].
    Kameda K; Kino C
    Kekkaku; 1974 Nov; 49(11):387-91. PubMed ID: 4455991
    [No Abstract]   [Full Text] [Related]  

  • 16. Hong Kong Treatment Services-Royal Postgraduate Medical School-British Medical Research Council Co-operative study of rifampicin plus ethambutol in daily and intermittent regimens. Clinical observations on adverse reactions.
    Girling DJ
    Scand J Respir Dis Suppl; 1973; 84():119-24. PubMed ID: 4522064
    [No Abstract]   [Full Text] [Related]  

  • 17. Rifampicin-dependent antibodies in twice-weekly treated patients.
    Algeorge G; Rudescu D; Alexandrescu D
    Scand J Respir Dis Suppl; 1973; 84():98-101. PubMed ID: 4522081
    [No Abstract]   [Full Text] [Related]  

  • 18. [Results of short course anti-tuberculous treatment (author's transl)].
    Yáñez A; Valenzuela P
    Rev Med Chil; 1981 Jul; 109(7):695-9. PubMed ID: 7330548
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term results of treatment with rifampicin and ethambutol in hyperchronic pulmonary tuberculosis with polyresistant bacilli].
    Anastasatu C; Sibila S
    Ftiziologia; 1973; 22(5):477-84. PubMed ID: 4751363
    [No Abstract]   [Full Text] [Related]  

  • 20. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
    Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.